Mycophenolate mofetil showed no clear difference in frequent relapses at 12 months compared with levamisole (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether mycophenolate mofetil changes adverse effects: peritonitis compared with levamisole (very low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: abdominal pain compared with levamisole (low certainty).
It is very uncertain whether mycophenolate mofetil changes adverse effects: anaemia compared with levamisole (very low certainty).
It is very uncertain whether mycophenolate mofetil changes adverse effects: leukopenia compared with levamisole (very low certainty).
Mycophenolate mofetil showed no clear difference in relapse at 12 months compared with cyclosporin (low certainty).
The review found no eligible studies for this question.
Mycophenolate mofetil showed no clear difference in adverse effects: hypertension compared with cyclosporin (low certainty).
Mycophenolate mofetil may leads to lower adverse effects: hypertrichosis compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: lymphopenia compared with cyclosporin (low certainty).
Mycophenolate mofetil may leads to lower adverse effects: gum hypertrophy compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in adverse effects: reduced GFR compared with cyclosporin (low certainty).
Mycophenolate mofetil showed no clear difference in relapses at 12 months compared with levamisole (low certainty).